This result may imply an important method to stratify early-stage nodal DLBCL patients based on the level of interferon and a potential therapeutic target suggesting the potential future inclusion of IFN-γ or IFN-γ analogue in combined therapies for early-stage nodal DLBCL patients with tumors under the diaphragm. This evidence concerns the gene IFNG and diffuse large B-cell lymphoma.